![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GLB1L3 |
Gene summary for GLB1L3 |
![]() |
Gene information | Species | Human | Gene symbol | GLB1L3 | Gene ID | 112937 |
Gene name | galactosidase beta 1 like 3 | |
Gene Alias | GLB1L3 | |
Cytomap | 11q25 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q8NCI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
112937 | GLB1L3 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.31e-18 | 5.45e-01 | -0.0166 |
112937 | GLB1L3 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.12e-26 | 6.94e-01 | -0.0132 |
112937 | GLB1L3 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 5.10e-22 | 6.35e-01 | -0.013 |
112937 | GLB1L3 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 8.40e-12 | 4.36e-01 | -0.0121 |
112937 | GLB1L3 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 3.64e-01 | -0.0961 |
112937 | GLB1L3 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 2.91e-02 | 3.23e-01 | -0.0822 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLB1L3 | insertion | Frame_Shift_Ins | novel | c.1786_1787insATTATGGATTTGTGTTCATCAATGGACGTAAATCCATAATTCCATTTCTGAAAGGAATGGT | p.Asn606LysfsTer21 | p.N606Kfs*21 | Q8NCI6 | protein_coding | TCGA-G3-A25S-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sunitinib | PD | ||
GLB1L3 | SNV | Missense_Mutation | c.1202N>A | p.Pro401His | p.P401H | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-05-5428-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR | |
GLB1L3 | SNV | Missense_Mutation | novel | c.1819N>A | p.Leu607Ile | p.L607I | Q8NCI6 | protein_coding | deleterious(0.01) | possibly_damaging(0.668) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLB1L3 | SNV | Missense_Mutation | novel | c.1499G>T | p.Arg500Met | p.R500M | Q8NCI6 | protein_coding | deleterious(0.02) | benign(0.04) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
GLB1L3 | SNV | Missense_Mutation | c.1369N>A | p.Tyr457Asn | p.Y457N | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-97-A4M7-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GLB1L3 | SNV | Missense_Mutation | novel | c.664G>T | p.Val222Leu | p.V222L | Q8NCI6 | protein_coding | tolerated(0.08) | benign(0.434) | TCGA-99-8028-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GLB1L3 | SNV | Missense_Mutation | c.716C>A | p.Pro239Gln | p.P239Q | Q8NCI6 | protein_coding | tolerated(0.11) | benign(0.111) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GLB1L3 | SNV | Missense_Mutation | c.1454N>T | p.Gly485Val | p.G485V | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-18-5592-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
GLB1L3 | SNV | Missense_Mutation | novel | c.131N>T | p.Ala44Val | p.A44V | Q8NCI6 | protein_coding | tolerated(0.38) | benign(0) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GLB1L3 | SNV | Missense_Mutation | novel | c.424N>C | p.Asp142His | p.D142H | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-33-AASJ-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |